Back to top

PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects

Read MoreHide Full Article

PerkinElmer, Inc. (PKI - Free Report) recently announced CE-IVD mark for commercialization and distribution of its Vanadis NIPT (non-invasive prenatal testing) system throughout Europe and countries that recognize the marking. However, Vanadis NIPT is not available for clinical use in the United States yet.

The latest development is likely to fortify PerkinElmer’s hold in the global non-invasive prenatal testing market.

Following the announcement, shares of PerkinElmer rose 0.3% to $82.76 at close. Over the past year, shares of PerkinElmer have rallied 12.6% against the industry’s 5.7% decline. The current level is also higher than the S&P 500 index’s 1% rise.

The stock carries a Zacks Rank #3 (Hold).

More on Vanadis NIPT

Vanadis NIPT enables pregnant women to receive reliable and accurate cell free DNA-based screenings through a cost-efficient method. The non-invasive system provides screening results for trisomy 21, trisomy 18 and trisomy 13.

The company has also collaborated with Women & Infants Hospital of Rhode Island to evaluate an innovative test method using Vanadis NIPT.

For investors’ notice, Sweden-based Vanadis Diagnostics was acquired by PerkinElmer in 2016, with a view to improve maternal and fetal health offerings.

A Peek Into NIPT Market

MarketsandMarkets opines that the global NIPT market is expected to reach $2.88 billion by 2021 at a CAGR of 16.4%. Growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT and launch of advanced NIPT products are fueling growth.

Hence the regulatory approval has been a well-timed one for the Massachusetts-based provider of scientific instruments.

Some key players in the space who deserve mention are Illumina (ILMN - Free Report) and Natera (NTRA - Free Report) . Notably, Illumina’s VeriSeq NIPT Solution and Natera’s Panorama next-generation NIPT are currently much in demand.

A Key Pick

A better-ranked stock in the broader medical space is Veeva Systems (VEEV - Free Report) .

Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Veeva Systems Inc. (VEEV) - free report >>

PerkinElmer, Inc. (PKI) - free report >>

Illumina, Inc. (ILMN) - free report >>

Natera, Inc. (NTRA) - free report >>

More from Zacks Analyst Blog

You May Like